Trial Profile
A phase I-II, open-label study of RAD001 [everolimus] in combination with Gleevec [imatinib; ST 1571] in refractory/resistant gastrointestinal stromal tumors.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 30 Jun 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 03 Jun 2021 Number of treatment arms increased form 1 to 6 by introducing additional dose levels for Imatinib and Everolimus, single-group assignment is changed to sequential assignment. Additional Safety primary end-point is also introduced, thus adding "AR" as the trial focus.
- 31 May 2012 Additional locations identified as reported by ClinicalTrials.gov.
- 11 Jan 2011 Primary endpoint identified as (Pharmacokinetic-parameters, Objective-clinical-response) as reported by ClinicalTrials.gov.